Skip to content
My WebMD Sign In, Sign Up

Brain Cancer Health Center

Font Size

Genetic Defect at Work in Deadly Brain Tumors

1 in 4 Glioblastomas May Have Newly Discovered Fault in Gene

Hope for New Treatments

The discovery of the NFKBIA gene and how it contributes to this kind of cancer may soon allow doctors to test patients for the gene and give them treatments that may correct for the genetic deficiency.

“The home run will be if we can identify patients with this defect and find out if a neutralization of this pathway actually helps them,” Aldape says.

There’s already some evidence that such a strategy could work.

The new study also found that boosting the expression of I-kappa-B in cancer cells that carry the NFKBIA deletion makes them more vulnerable to a chemotherapy drug called Temodar.

There’s a study already under way at Northwestern University that is testing a drug called Velcade, which helps to stabilize levels of the I-kappa-B protein in cancer cells.

The hope is that Velcade, or another as-yet-undiscovered medication, could first be given to patients to help sensitize cancer cells to a next wave of chemotherapy or radiation treatments that could then finish them off.

If that happens, experts say it could be the first real spark of hope in a cancer where diagnosis is nearly always a death sentence.

“I’ve been focusing on brain tumors for one-quarter of a century,” says Harsh, “and it’s heart wrenching to lose patient after patient.”


Today on WebMD

human brain xray
Computed Tomography CT Scan Of The Head
Integrative Medicine Cancer Quiz
what is your cancer risk
Health Check

Malignant Gliomas
Pets Improve Your Health
Headache Emergencies
life after a brain tumor

Would you consider trying alternative or complementary therapies?

WebMD Special Sections